Story excerpt…
Today the U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). Enzalutamide was previously approved only for patients with metastatic CRPC. Prior to this past February – when the FDA also approved apalutamide (Erleada) for non-metastatic CRPC – there were no FDA-approved treatments for these men.
Read the full story
Prostate Cancer Foundation
About the Mike Slive Foundation
The Mike Slive Foundation endeavors to become a global leader in the fight to eradicate prostate cancer through public awareness and research funding in memory of Mike Slive, a transformative leader whose vision and direction revolutionized the business of collegiate sports.
Founded in Birmingham, Alabama, by attorney Ed Meyerson and former SEC Commissioner Mike Slive, the Mike Slive Foundation for Prostate Cancer Research is dedicated to funding groundbreaking prostate cancer research and raising awareness about the importance of early detection. Since 2017, the Foundation has invested more than $4 million in research grants while working to improve outcomes for men and families affected by prostate cancer. Follow us on Twitter, Facebook and Instagram @MikeSliveFdn.
David Barry
Marketing and Communications Consultant
(205) 910-3832
David@MikeSliveFoundation.org
